-

GeneDx to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:

  • Stifel 2025 Healthcare Conference

New York, New York

Fireside Chat: Wednesday, November 12 at 2:00 p.m. ET

  • Jefferies Global Healthcare Conference

London, UK

Presentation: Wednesday, November 19 at 11:00 a.m. GMT

  • Piper Sandler 37th Annual Healthcare Conference

New York, New York

Fireside Chat: Wednesday, December 3 at 1:30 p.m. ET

Live and archived webcasts of the presentations will be available on the “Events” section of the GeneDx investor relations website at ir.genedx.com/news-events/events.

About GeneDx
GeneDx (Nasdaq: WGS) is the global leader in rare disease diagnosis, transforming the way medicine is practiced by making genomics the starting point for health, not the last resort. We bring together unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the largest rare disease dataset – built over 25 years from millions of genomic tests and deep clinical insights. This unparalleled foundation powers our ExomeDx™ and GenomeDx™ tests, giving clinicians the highest likelihood of delivering a timely, accurate diagnosis. GeneDx is shaping the future of healthcare by moving the standard of care from sick care to proactive healthcare. While our roots are in rare disease diagnosis, our commitment extends beyond – growing with the families we serve – as a trusted partner at every stage of life. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

Contacts

Investor Relations Contact:
Investors@GeneDx.com

Media Contact:
Press@GeneDx.com

GeneDx

NASDAQ:WGS

Release Versions

Contacts

Investor Relations Contact:
Investors@GeneDx.com

Media Contact:
Press@GeneDx.com

More News From GeneDx

GeneDx Announces Preliminary 2025 Financial Results and Provides 2026 Guidance

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx reported high growth and profitability in preliminary results for the fourth quarter and full year of 2025 and issued 2026 guidance....

GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Komodo Health Partner to Build the World’s Most Complete Longitudinal Rare Disease Dataset...

GeneDx Announces GenomeDx Prenatal™, Expanding Industry-Leading Genomic Diagnosis Into Prenatal Care

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx announced GenomeDx Prenatal™, a whole genome sequencing test that delivers fast, comprehensive insights when fetal anomalies are identified....
Back to Newsroom